Arogya Aarohan app & other AI-driven tools are being tested for early detection of diseases as part of Rs 300-cr initiative ...

The impact of this programme over two decades has been considerable—it has facilitated early diagnosis and prompt treatment for both proliferative diabetic retinopathy and diabetic macular oedema; ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.

Diabetic nephropathy is the leading cause ... evaluation regarding the presence of comorbid associations, especially retinopathy and macrovascular disease. Achieving the best metabolic control ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

Health scientists from the University of Virginia have found a previously unknown contributor to harmful blood vessel growth ...

About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...

Carol Yepes via Getty A little donated poop may go a long way for people with type 1 diabetes. New research published ... later round of treatment, all of the patients were given FMT).

Retinal Biologics Industry. The retinal biologics market experienced significant growth in 2021, with total revenue reaching ...

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...